12:00 AM
Jun 29, 2009
 |  BioCentury  |  Strategy

Merger meets Emergency

When research tool provider Invitrogen Corp. acquired instrument company Applied Biosystems Group in 2008, both companies derived the majority of their revenues from consumables. However, Invitrogen's historical strengths lay in the sample preparation and processing end of the laboratory workflow, while ABI's historical strengths lay at the other end, in instrumentation and reagents optimized for its own systems.

The merger's rationale was put to the test on April 23, when the U.S. Centers for Disease Control asked the now renamed Life Technologies Corp. for help tracking and monitoring the outbreak of swine influenza. The agency had developed a swine influenza assay to run on the company's real-time PCR instrument.

CDC was seeking emergency use authorization (EUA), which meant the instrument also would have to be given emergency clearance. The company also would have to rapidly upgrade research use only (RUO) instruments already in the field, as well as step up its production of new diagnostic-use (Dx) machines.

By establishing a task force that included employees from both predecessor companies, the biotech was able to provide a coordinated response to CDC that would not have been possible prior to the merger, President and COO Mark Stevenson told BioCentury.

The experience also has provided the company with...

Read the full 1023 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >